Blueprint Medicines Corp (BPMC) : Opaleye Management scooped up 535,000 additional shares in Blueprint Medicines Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 785,000 shares of Blueprint Medicines Corp which is valued at $27,475,000.Blueprint Medicines Corp makes up approximately 14.65% of Opaleye Management’s portfolio.
Other Hedge Funds, Including , Group One Trading reduced its stake in BPMC by selling 749 shares or 83.22% in the most recent quarter. The Hedge Fund company now holds 151 shares of BPMC which is valued at $5,285. Dekabank Deutsche Girozentrale sold out all of its stake in BPMC during the most recent quarter. The investment firm sold 16,100 shares of BPMC which is valued $482,195. Victory Capital Management Inc added BPMC to its portfolio by purchasing 815,410 company shares during the most recent quarter which is valued at $22,847,788. Blueprint Medicines Corp makes up approx 0.07% of Victory Capital Management Inc’s portfolio. Hamilton Lane Advisors sold out all of its stake in BPMC during the most recent quarter. The investment firm sold 21,034 shares of BPMC which is valued $631,020.
Blueprint Medicines Corp opened for trading at $36.18 and hit $36.47 on the upside on Monday, eventually ending the session at $36.34, with a gain of 0.94% or 0.34 points. The heightened volatility saw the trading volume jump to 1,21,097 shares. Company has a market cap of $993 M.
On the company’s financial health, Blueprint Medicines Corp reported $-0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Nov 10, 2016. Analyst had a consensus of $-0.79. The company had revenue of $6.16 million for the quarter, compared to analysts expectations of $6.06 million. The company’s revenue was up 79.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.47 EPS.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib which is an inhibitor of KIT and PDGFRa is approved in SM and GIST. The Company’s other drug candidate is BLU-554 which targets FGFR4 a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.